NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight patients into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback